Global Single-Use Bioreactors Market Development, Overview, and Forecast to 2030
Single-use bioreactors are a revolutionary product of the process optimization efforts of drug manufacturers, offering a highly flexible approach to rapidly produce multiple drugs, while notably reducing downtime between batches and operational costs
Roots Analysis has announced the addition of “Single-Use Bioreactors Market, 2021-2030” report to its list of offerings.
Traditionally, stainless steel bioreactors were the preferred choice for production of biologics; however, over the past couple of decades, biopharmaceutical manufacturing has gradually witnessed a shift towards the use of single-use technologies. Apart from low contamination risk and better product yield, single-use bioreactors are easy-to-install and have a much smaller footprint, compared to the traditional stainless steel systems.
Key Market Insights
160 single-use bioreactors are currently available / under development for different scales of operation
It is worth noting that most of the single-use bioreactors (49%) are stirred tank bioreactors, followed by pneumatically mixed bioreactors (9%). It is worth highlighting that nearly 70% of single-use bioreactors support laboratory scale operations.
Majority (40%) of the single-use bioreactors are intended for mammalian cell culture
Presently, several bioreactors are also being used to culture appropriate host cells for studying the pathogenesis of the novel coronavirus. Other popular application areas for single-use bioreactors include stem cell research (47%), and cancer research (20%).
Close to 40 players are driving the activity within the single-use bioreactors industry
Majority (47%) of the initiatives in this domain are led by small-sized firms, followed by mid-sized (24%) and large players (29%). Further, around 60% of the firms engaged in providing single-use bioreactors were established post 2000.
Partnership activity in this field has grown at a CAGR of ~16%, between 2015 and 2020
Nearly 45% of the reported deals were established after 2015, with the maximum activity being reported in 2017. Majority of the partnerships inked within this domain were product / technology integration agreements (30%), followed by full business acquisitions (22%) and product / technology development agreements (15%).
2,800+ patents that have been filed / granted for single-use bioreactors, till 2020
Based on the intellectual property distribution across the world, R&D activity related to single-use bioreactors is largely concentrated in the US (around 47%). Majority of the patents in this field were filed by industry players (94%).
North America and Europe are anticipated to capture over 33.5% of the market share by 2030
The market in Asia-Pacific are anticipated to grow at a relatively faster rate (over 20%). In 2030, mammalian cell cultures are likely to capture the largest market share (36%) in terms of revenues from product sales, followed by viral cell cultures (20%), microbial cell cultures (15%) and insect cell cultures (11%).
Key Questions Answered
- Who are the leading manufacturers engaged in the development of single-use bioreactors?
- What are the different applications of single-use bioreactors?
- Which partnership models are commonly adopted by stakeholders in this industry?
- Which features of single-use bioreactors are most important to end-users?
- What are the challenges currently faced by stakeholders in this industry?
- What are the key factors that are likely to influence the evolution of this market?
- How has the COVID-19 pandemic impacted the single-use bioreactors market?
- How is the current and future opportunity likely to be distributed across key market segments?
- What are the anticipated future trends related to single-use bioreactors?
The USD 6.6 billion (by 2030) financial opportunity within the single-use bioreactors market has been analysed across the following segments:
Type of Cell Culture
- Bacterial Cell Cultures
- Insect Cell Cultures
- Mammalian Cell Cultures
- Microbial Cell Cultures
- Plant Cell Cultures
- Viral Cell Cultures
- Other Cell Cultures
Type of Molecule
- Cell Therapies
- Gene Therapies
- Monoclonal Antibodies
- Recombinant Proteins
- Stem Cell Therapies
- Other Molecules
- Cancer Research
- Drug Discovery and Toxicity Testing
- Regenerative Medicine and Tissue Engineering
- Stem Cell Research
- Other Application Areas
Scale of Operation
- Small Scale Operations
- Large Scale Operations
- Research and Development
- Biopharmaceutical Manufacturing
- Biopharmaceutical / Pharmaceutical Industries
- Academic / Research Institutes
Key Geographical Regions
- North America
- Latin America (LATM)
- Middle East and North Africa (MENA)
- Rest of the World (RoW)
The report features inputs from eminent industry stakeholders, according to whom, the US is likely to dominate this market, despite the fact that the country is currently facing several political challenges, as well as problems related to the COVID-19 pandemic. The report includes detailed transcripts of discussions held with the following industry experts:
- Per Stobbe (Chief Executive Officer, Marketing, Technical Support, CerCell)
- Torsten Due Bryld (Chief Commercial Officer, CelVivo)
The research includes detailed profiles of key players (listed below) engaged in the development of single-use bioreactors; each profile features an overview of the developer, details related to its product portfolio, and recent developments, and an informed future outlook:
- Cell Culture Company
- CESCO Bioengineering
- Merck Millipore
- Pall Corporation
- PBS Biotech
- Pierre Guerin
- Sartorius Stedim Biotech
- Solaris Biotech
- Thermo Fisher Scientific
Also have a Look on Our Upcoming Research Reports